Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the ...

MannKind (NASDAQ:MNKD) will buy scPharmaceuticals (NASDAQ:SCPH) for an equity value of approximately $303M and a total deal ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceuticals shareholders. Under the ...

Fintel reports that on August 25, 2025, Maxim Group downgraded their outlook for scPharmaceuticals (NasdaqGS:SCPH) from Buy ...

Key Points Revenue (GAAP) nearly doubled year over year to $16.0 million in Q2 2025, surpassing analyst estimates by 3.8%. Prescription growth for FUROSCIX was strong following its launch into chronic ...

scPharmaceuticals Inc. Annual stock financials by MarketWatch. View the latest SCPH financial statements, income statements and financial ratios.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceuticals shareholders. Under ...

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

scPharmaceuticals Inc. Annual cash flow by MarketWatch. View SCPH net cash flow, operating cash flow, operating expenses and cash dividends.